Inhibikase Therapeutics (IKT) Short-term Investments (2022 - 2026)

Inhibikase Therapeutics (IKT) has reported Short-term Investments for 5 consecutive years, with $120.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Short-term Investments rose 511.97% year-over-year to $120.8 million; the TTM figure through Mar 2026 stood at $120.8 million (up 511.97% YoY), while the FY2025 annual figure was $39.5 million, down 3.68% from the prior year.
• Short-term Investments rose to $120.8 million in Q1 2026 per IKT's latest filing, from $39.5 million in the prior quarter.
• Across five years, Short-term Investments topped out at $120.8 million in Q1 2026 and bottomed at $2.0 million in Q3 2023.
• Historically, Short-term Investments has averaged $24.5 million across 5 years, with a median of $19.0 million in 2023.
• Annual changes were most pronounced in 2023 — Short-term Investments tumbled 90.51% — and 2025, when it surged 1575.91%.
• Inhibikase Therapeutics' Short-term Investments stood at $15.9 million in 2022, then tumbled by 74.23% to $4.1 million in 2023, then soared by 904.51% to $41.1 million in 2024, then dropped by 3.68% to $39.5 million in 2025, then soared by 205.47% to $120.8 million in 2026.
• Business Quant data shows IKT's Short-term Investments at $120.8 million in Q1 2026, $39.5 million in Q4 2025, and $39.1 million in Q3 2025.